Familial hypercholesterolaemia: identification and management
KEYWORDS: people, healthcare, disease, therapy, coronary, healthcare professionals, professionals, children, heart disease, coronary heart, heart, concentration, risk, ldl-c, drug

of onset of coronary heart disease within the family, and • the presence of other cardiovascular risk factors, including their LDL-C concentration. [2008] 1.3.1.19 When offering lipid-modifying drug therapy for children or young people, healthcare professionals should inform the child or young person and their parent or carer that this treatment should be lifelong. [2008] 1.3.1.20 Offer statins to children with FH by the age of 10 years or at the earliest opportunity thereafter. [2017] 1.3.1.21 For children and young people with FH, consider a statin that is licensed for use in the appropriate age group. [2017] 1.3.1.22 Statin therapy for children and young people should be initiated by a healthcare professional with expertise in treating children and young people with FH, and in a child-focused setting. [2008, amended 2017] 1.3.1.23 Statin therapy for children and young people with FH should usually be prescribed at the doses specified in the 'British national formulary (BNF) for children'. [2008] 1.3.1.24 In exceptional instances, for example, when there is a family history of coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering: • a higher dose of statin than is licensed for
